Ssc. Chang et al., The Asia-Pacific Guidelines for 'Indigo' interstitial laser coagulation inthe management of benign prostatic hyperplasia, MIN INVAS T, 9(6), 2000, pp. 411-422
A panel of urologists experienced in interstitial laser coagulation (ILC) g
athered to formulate practice guidelines for ILC. The aim was to avoid abus
e or inappropriate applications leading to problems that may jeopardise the
welfare of patients, and to formulate a common rationale for treatment to
facilitate reimbursement for benign prostatic hyperplasia (BPH) treatment i
n Asia-Pacific countries and elsewhere. The authors reviewed data from the
literature and accumulated experience from over 1000 patients who have unde
rgone ILC since 1991. ILC for BPH treatment is a safe procedure with a low
complication profile and its effectiveness is comparable to that of transur
ethral resection of the prostate (TURP). Temporary voiding irritation for 2
-4 weeks and a catheterisation period of 5-7 days are the major disadvantag
es seen in those who had eight punctures or more for their BPH. Despite the
seemingly higher direct cost arising from investment in laser unit and fib
re-optic equipment, other benefits of ILC - such as short hospitalisation,
early return to work, treatment safety and low complication profile - outwe
igh this initial outlay and make ILC an economical treatment option. ILC is
an easy-to-learn, safe and effective procedure for BPH treatment. The low
morbidity profile makes ILC a valuable option for BPH patients who have ser
ious underlying disease, or who are poor surgical risks for TURF or other i
nvasive modalities.